article thumbnail

Looking Beyond mRNA-based COVID-19 Vaccines to Innovative Therapeutics

PharmaTech

The LNP-encapsulated small interfering RNA (siRNA) was approved by FDA for the treatment of hereditary transthyretin amyloidosis (ATTR), and this opened the door for mRNA-based drugs in many applications. News Release. Intellia Therapeutics. News Release. BioNTech Announces First Quarter 2025 Financial Results and Corporate Update | BioNTech.

article thumbnail

UK steps up with £1.25bn Gavi vaccine pledge as US funding disappears

Pharmaceutical Technology

I call on Gavi today to re-earn the public trust and to justify the $8bn that America has provided in funding since 2001,” he said in a video statement. In a move that reflects the country’s ongoing pullback from international aid , US health secretary Robert F Kennedy, Jr (RFK) claimed Gavi had ignored science. “I

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Brawl over Eylea gets biosimilar industry’s attention

STAT

AbbVie is paying $700 million upfront to acquire licensing rights to a “trispecific antibody” treatment for cancer developed by Ichnos Global Innovation. The drug, called ISB 2001, targets CD38 and BCMA protein receptors on tumor cells and the CD3 receptor on T cells.

article thumbnail

Opinion: STAT+: 3 keys to successful biopharma-academia drug development collaborations

STAT

Academia can be an excellent source of novel drug targets and new technologies that can enhance medicinal discovery. Indeed, academic inventors or founders contributed to more than one-quarter of all medicines approved from 2001 through 2019. Yet many sponsored research collaborations that hope to tap into academia fail.

article thumbnail

Opinion: STAT+: A California court is setting a dangerous precedent over drug development (or lack thereof) liability

STAT

Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

article thumbnail

The Important Role that Biopharmaceutics Plays in Accelerating Early-Phase Drug Development

Pharmaceutical Technology

As formulators, we are often able to directly impact the amount of drug absorbed through formulation optimization and improve exposure. However, the chances of improving the exposure profile of a drug that is highly cleared by formulation modification are limited. S54 – S61 (2001).

article thumbnail

2022 spells change for EU pharmaceutical legislation

European Pharmaceutical Review

But what are the key potential changes and how could they impact drug developers and manufacturers? He noted that within the proposals, there is likely to be a differentiation in incentives for drug development in the orphan and unmet medical need areas. Key areas of potential legislative change. Future outlook.